title: Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study.
abstract: BACKGROUND
  The purpose of this study was to investigate the effect of glibenclamide dose escalation on blood glucose and insulin in patients with poorly controlled type 2 diabetes.
  
  
  METHODS
  Twenty-two subjects with type 2 diabetes were administered increasing doses (0, 2.5, 5, 10, and 20 mg/day) of glibenclamide at 2-week intervals. Glibenclamide, glucose, and insulin determinations were performed.
  
  
  RESULTS
  The decrease in mean blood glucose from zero dose was 20%, 22%, 26%, and 28% for doses of 2.5, 5, 10, and 20 mg/day, respectively, which was significant from zero dose to 2.5 mg/day (P≤0.001). There were no significant decreases in glucose concentration beyond 2.5 mg/day. The percentage increase in mean insulin from zero dose was 51%, 58%, 44%, and 33% for 2.5, 5, 10, and 20 mg/day respectively. Mean blood insulin increased significantly from zero dose to 2.5 mg/day (P≤0.001). There were no significant increases in mean insulin concentration beyond 2.5 mg/day.
  
  
  CONCLUSIONS
  The results of this study suggest that increasing doses of glibenclamide do not produce a proportional increase in insulin secretion or a proportional decrease in blood glucose concentration.
authors.affiliation: Biomedical Research Ethics Committee, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa.
authors.forename: Virendra
authors.initials: V
authors.lastname: Rambiritch
authors.affiliation: Department of Therapeutics and Medicines Management, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa.
authors.forename: Breminand
authors.initials: B
authors.lastname: Maharaj
authors.affiliation: Boehringer-Ingelheim, Medical Affairs, Johannesburg, Gauteng, South Africa.
authors.forename: Poobalan
authors.initials: P
authors.lastname: Naidoo
keywords: dose-escalation; glibenclamide; glucose; insulin; type 2 diabetes
references.citation: South Med J. 2007 Nov;100(11):1132-6
references.pmid: 17984746
references.citation: Diabetes Care. 1991 Aug;14(8):724-7
references.pmid: 1954808
references.citation: Diabetes Care. 1987 Nov-Dec;10(6):671-8
references.pmid: 3123184
references.citation: J Clin Pharm Ther. 1989 Jun;14(3):181-8
references.pmid: 2503528
references.citation: J Am Coll Cardiol. 2003 Sep 17;42(6):1017-21
references.pmid: 13678923
references.citation: Diabetes Obes Metab. 2001 Dec;3(6):403-9
references.pmid: 11903411
references.citation: Heart. 2004 Jan;90(1):9-12
references.pmid: 14676228
references.citation: Horm Metab Res. 1983 Sep;15(9):425-8
references.pmid: 6416980
references.citation: Br J Clin Pharmacol. 1997 Apr;43(4):373-81
references.pmid: 9146849
references.citation: S Afr Med J. 1989 Sep 16;76(6):286
references.pmid: 2506654
references.citation: Drug Saf. 1994 Oct;11(4):223-41
references.pmid: 7848543
references.citation: S Afr Med J. 2007 Jul;97(7):475
references.pmid: 17805443
references.citation: Pharmacotherapy. 1985 Mar-Apr;5(2):43-62
references.pmid: 3923453